Prelude Therapeutics Incorporated

PRLD XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

280M

Short interest (May 15)

2.3%

Net Short (Jun 03 ): 0.0%

Borrow Fee

1.14%

↓ 6.7%

Available Shares

↓ 5.1%

Price Chart

Company Overview

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001678660

Asset Type: CS

Market Data

Market Cap: $278,758,574

Employees: 79

Status: Active

Short Interest

Current Borrow Fee 1.14%

Range: 1.14% - 1.14%

Available Shares 1M

Range: 1M - 1.4M

Recent Changes

Fee Change: ↑ 0.1%

Available Change: ↓ 3.5%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime